An open-label, single-treatment, single-period, single dose, clinical phase 1 study to assess the safety and tolerability of Bivalent Human Papillomavirus (Types 16 L1 & 18 L1) Vaccine of M/s Cadila Healthcare Ltd., India in healthy, adult, female, human subjects

Trial Profile

An open-label, single-treatment, single-period, single dose, clinical phase 1 study to assess the safety and tolerability of Bivalent Human Papillomavirus (Types 16 L1 & 18 L1) Vaccine of M/s Cadila Healthcare Ltd., India in healthy, adult, female, human subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Human papillomavirus vaccine (Primary)
  • Indications Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 01 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top